nach oben

Erschienen in:

16.01.2019 | Gynecologic Endocrinology and Reproductive Medicine

Oviductus Ranae protein hydrolyzate prevents menopausal osteoporosis by regulating TGFβ/BMP2 signaling

verfasst von: Xiaohua Li, Xin Sui, Qing Yang, Yinqing Li, Na Li, Xiaozheng Shi, Dong Han, Yiping Li, Xiaowei Huang, Peng Yu, Xiaobo Qu

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

It is known that menopausal osteoporosis (MOP) is the most typical form of osteoporosis, which is characterized by low bone mass and microstructure damage of the bone tissue, leading to increased bone fragility and risk of fracture. This study aimed to evaluate the protective effects of Oviductus Ranae protein hydrolyzate (ORPH) on the MOP in vivo.

Methods

Osteoporosis model was induced by ovariectomy, treated with ORPH 150 or 75 mg kg⁻¹. Body weight and bone mineral density (BMD) of rats were measured at the beginning and the end of the experiment, and femoral maximum load was determined immediately after killing. The expression levels of alkaline phosphatase (ALP), Smad4, tartrate acid phosphatase (TRAP), BMP2, Runx2, CPB, ColI and osteocalcin were examined by RT-PCR or western-blotting. HE staining was used to observe the pathological changes in the femurs. Immunohistochemistry was used to detect the expression of ALP and BMP2. All data were analyzed by SPSS 13.0.

Results

The results revealed that ORPH had no effect on the weight of normal and osteoporotic rats. ORPH could significantly improve the femur BMD and increase the maximum load of the osteoporotic rats. ORPH could significantly upregulate the expression level of bone formation makers, ALP, osteocalcin, ColI, and Runx2, and downregulate the expression level of bone resorption marker, TRAP. In the ORPH group, the expression levels of BMP2, Smad4, and CPB of key proteins in the TGFβ/BMP2 signaling pathway were significantly upregulated. In addition, immunohistochemistry showed that ALP and BMP2 expression in femurs of the ORPH group was stranger. H&E staining showed that ORPH (150 mg kg⁻¹) significantly increased the thickness of trabeculae and decreased fracture risk.

Conclusion

Collectively, ORPH plays a role in the prevention and treatment of osteoporosis, which may be a potential anti-osteoporosis drug.

National Pharmacopoeia Committee (2010) Pharmacopoeia of People’s Republic of China, Part 1. Chinese Medical Science and Technology Press, Beijing, p 239

Mousavi A, Nadjar Araabi B, Nili Ahmadabadi M (2014) Context transfer in reinforcement learning using action-value functions. Comput Intell Neurosci 14:428–433

Wang DH, Wu W, Tian JM, Wang ZH, Wang DT, Xiang K, Zhu GY, Han T (2013) Effect of Oviductus ranae and Oviductus ranae eggs on bone metabolism and osteoporosis. Chin J Integr Med 19(7):532–538CrossRefPubMed

Cairoli E, Zhukouskaya VV, Eller-Vainicher C, Chiodini I (2015) Perspectives on osteoporosis therapies. J Endocrinol Investig 38(3):303–309CrossRef

Liang L, Zhang XH, Zhou Y, Huang YJ, Deng HZ (2008) Protective effect of Oviductus Ranae capsules on the reproductive organs of aged mice. Nan Fang Yi Ke Da Xue Xue Bao 28:982–985PubMed

Du X, Xu S, Wang W (1998) Research progress on deglycosylation of mucin glycoprotein. Nat Prod Res Dev 04:94–98

Woolf AD, Pfleger B (2003) Burden of major musculoskeletal conditions. Bull World Health Organ 81:646–656PubMedPubMedCentral

Melton LJ III, Johnell O, Lau E, Mautelen CA, Seeman E (2004) Osteoporosis and the global competition for health care resources. J Bone Miner Res 19:1055–1058CrossRefPubMed

Feldbrin Z, Luckish A, Shargorodsky M (2016) Effects of long-term risedronate treatment on serum ferritin levels in post-menopausal women with osteoporosis: the impact of cardiovascular risk factor load. Menopause 23:55–59CrossRefPubMed

10.

Romas E (2005) Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates. Best Pract Res Clin Rheumatol 19:1065–1079CrossRefPubMed

11.

Reid IR (2015) Short-term and long-term effects of osteoporosis therapies. Nat Rev Endocrinol 11:418–428CrossRefPubMed

12.

Cummings SR, Melton JR III (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:176–177CrossRef

13.

Feng M, Zhang R, Gong F, Yang P, Fan L, Ni J, Bi W, Zhang Y, Wang C, Wang K (2014) Protective effects of necrostatin-1 on glucocorticoid-induced osteoporosis in rats. J Steroid Biochem Mol Biol 144B:455–462CrossRef

14.

Samir SM, Malek HA (2014) Effect of cannabinoid receptors 1 modulation on osteoporosis in a rat model of different ages. J Physiol Pharmacol 65:687–694PubMed

15.

Jin H, Evangelou E, Ioannidis JPA, Ralston SH (2011) Polymorphisms in the 5′ flank of COL1A1 gene and osteoporosis: meta-analysis of published studies. Osteporos Int 22:911–921CrossRef

16.

Rojano-Mejía D, Coral-Vázquez RM, Espinosa LC (2013) JAG1 and COL1A1 polymorphisms and haplotypes in relation to bone mineral density variations in postmenopausal Mexican Mestizo women. Age 35:471–478CrossRefPubMed

17.

Ji GR, Yao M, Sun CY, Zhang L, Han Z (2009) Association of collagen type I alpha1 (COLIA1) Sp1 polymorphism with osteoporotic fracture in Caucasian post-menopausal women: a metaanalysis. J Int Med Res 37:1725–1732CrossRefPubMed

18.

Gundberg CM (2000) Biochemical markers of bone formation. Clin Lab Med 20:489–501CrossRefPubMed

19.

Ohara N, Hayashi Y, Yamada S, Kim SK, Matsunaga T (2004) Early gene expression analyzed by cDNA microarray and RT-PCR in osteoblasts cultured with water-soluble and low molecular chitooligosaccharide. Biomaterials 25:1749–1754CrossRefPubMed

20.

Jönsson S, Hjorth-Hansen H, Olsson B, Wadenvik H, Sundan A (2012) Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro. J Bone Miner Metab 30:119–123CrossRefPubMed

21.

Clarke B (2008) Normal bone anatomy and physiology. Clin J Am Soc Nephrol 3:S131–S139CrossRefPubMedPubMedCentral

22.

Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GW, Beddington RS, Mundlos S, Olsen BR, Selby PB, Owen MJ (1997) Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89:765–771CrossRefPubMed

23.

Otto F, Kanegane H, Mundlos S (2002) Mutations in the RUNX2 gene in patients with cleidocranial dysplasia. Hum Mutat 19:209–216CrossRefPubMed

24.

Yoshida T, Kanegane H, Osato M, Yanagida M, Miyawaki T, Ito Y, Shigesada K (2003) Functional analysis of RUNX2 mutations in cleidocranial dysplasia: novel insights into genotype–phenotype correlations. Blood Cells Mol. Dis 30:184–193CrossRefPubMed

25.

Zhang XN, Chen K, Wei B (2016) Ginsenosides Rg3 attenuates glucocorticoid-induced osteoporosis through regulating BMP-2/BMPR1A/Runx2 signaling pathway. Chem Biol Interact 25(6):188–197CrossRef

26.

Lee AJ, Hodges S, Eastell R (2000) Measurement of osteocalcin. Ann Clin Biochem 37:432–446CrossRefPubMed

27.

Charles P, Poser JW, Mosekilde L, Jensen FT (1985) Estimation of bone turnover evaluated by 47Ca-kinetics. Efficiency of serum bone gamma-carboxyglutamic acid-containing protein, serum alkaline phosphatase, and urinary hydroxy-proline excretion. J Clin Investig 76:2254–2258CrossRefPubMedPubMedCentral

28.

Delmas PD, Malaval L, Arlot ME, Meunier PJ (1985) Serum bone Gla-protein compared to bone histomorphometry in endocrine diseases. Bone 6:339–341CrossRefPubMed

29.

Urist MR (1997) Bone morphogenetic protein: the molecularization of skeletal system development. J Bone Miner Res 12:343–346CrossRefPubMed

30.

Medici M, van Meurs JB, Rivadeneira F, Zhao H, Arp PP, Salvatici M, Botteri E (2006) MP-2 gene polymorphisms and osteoporosis: the Rotterdam study. J Bone Miner Res 21(6):845–853CrossRefPubMed

31.

Kanzler B, Foreman RK, Labosky PA, Mallo M (2000) BMP signaling is essential for development of skeletogenic and neurogenic cranial neural crest. Development 127:1095–1104PubMed

32.

Spinella-Jaegle S, Roman-Roman S, Faucheu C, Dunn FW, Kawai S, Gallea S, Stiot V, Blanchet AM, Courtois B, Baron R, Rawadi G (2001) Opposite effects of bone morphogenetic Protein-2 and transforming growth factor-1 on osteoblast differentiation. Bone 29:323–330CrossRefPubMed

33.

Thies RS, Bauduy M, Ashton BA, Kurtzberg L, Wozney JM, Rosen V (1992) Recombinant human bone morphogenetic protein-2 induces osteoblastic differentiation in W-20-17 stromal cells. Endocrinology 130:1318–1324PubMed

34.

Zhang H, Bradley A (1996) Mice deficient for BMP2 are nonviable and have defects in amnion/chorion and cardiac development. Development 122:2977–2986PubMed

Titel: Oviductus Ranae protein hydrolyzate prevents menopausal osteoporosis by regulating TGFβ/BMP2 signaling
verfasst von: Xiaohua Li
Xin Sui
Qing Yang
Yinqing Li
Na Li
Xiaozheng Shi
Dong Han
Yiping Li
Xiaowei Huang
Peng Yu
Xiaobo Qu
Publikationsdatum: 16.01.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 3/2019
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-018-5033-9

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Rezidivierender Peritonsillarabszess nach Oralsex

02.05.2024 Peritonsillarabszess Kasuistik

Die erotischen Dimensionen von Peritonsillarabszessen scheinen eng begrenzt zu sein. Das heißt aber nicht, solche Abszesse und Erotik hätten nichts miteinander gemein, wie ein Fallbericht verdeutlicht.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Oviductus Ranae protein hydrolyzate prevents menopausal osteoporosis by regulating TGFβ/BMP2 signaling